Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections

11 Oct 2018

Abstract excerpt

Objectives: To describe the pharmacokinetic/pharmacodynamic (PK/PD) modelling and microbiological data that were used to support the recent European approval of ceftaroline fosamil 600 mg q8h by 2 h intravenous (iv) infusion for patients with complicated skin and soft tissue infections (cSSTIs) caused by Staphylococcus aureus with ceftaroline MICs of 2 or 4 mg/L, and the associated EUCAST MIC breakpoint update...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics Pharmacokinetics and Efficacy
Share to Antimicrobial Resistance in Staphylococcus
Share to Streptococcal Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30380060
DOI: 10.1093/jac/dky439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infectionsPMID 30380060Read ↗

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activitySemantic proximity Read ↗

In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.Semantic proximity Read ↗

Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.Semantic proximity Read ↗

Clinical Experience of Ceftaroline-Fosamil in Gram-Positive Infective Endocarditis: A Multicenter Real-World Observational StudySemantic proximity Read ↗

Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Semantic proximity Read ↗

I n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complexSemantic proximity Read ↗

The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.Semantic proximity Read ↗

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient SubgroupsSemantic proximity Read ↗

Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.Semantic proximity Read ↗

Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.Semantic proximity Read ↗

Penicillin allergy de-labeling in the critical care unit. Simulations to design an intravenous drug provocation test that mirrors the plasma profile of an enteral challengeSemantic proximity Read ↗

In vivopharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteriaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.